Preface

Area of Science:

• Infectious Diseases
• Pharmacology
• Urology

Background:

• Lower urinary tract infections (UTIs) are prevalent, accounting for significant general practitioner consultations and antibiotic prescriptions.
• Uropathogenic bacteria exhibit increasing resistance to common antibiotics like trimethoprim and ampicillin, exceeding 30-50% in many cases.
• Rapid development of resistance to fluoroquinolones necessitates exploring alternative treatment options for UTIs.

Purpose of the Study:

• To review current perspectives on the diagnosis and treatment of UTIs.
• To evaluate the role of pivmecillinam in managing UTIs amidst rising antimicrobial resistance.
• To discuss evolving treatment strategies, including shorter regimens and alternative antibiotics.

Main Methods:

• Review of scientific literature and clinical data on UTI treatment.
• Analysis of antibiotic resistance patterns for common UTI pathogens.
• Evaluation of pivmecillinam's pharmacological properties, including its mechanism of action, spectrum, and safety profile.

Main Results:

• High rates of resistance to trimethoprim and ampicillin are observed.
• Fluoroquinolone resistance can emerge rapidly, posing a clinical challenge.
• Pivmecillinam demonstrates a novel mode of action, good bacterial penetration, and a favorable safety profile.

Conclusions:

• The changing landscape of antimicrobial resistance requires reevaluation of UTI treatment strategies.
• Pivmecillinam's characteristics suggest it is a suitable candidate for treating common UTIs.
• Long-term clinical experience supports reconsidering pivmecillinam's role in UTI management.